Companies /Healthcare
Lantheus Holdings Inc
NASDAQ: LNTH Drug Manufacturers - Specialty & Generic
$101.60
▼ $0.02 (−0.02%) today
Markets closed · 11:03pm ET

Lantheus (LNTH) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
83%
EPS beat rate
+17.96%
Avg. EPS surprise
Consecutive EPS beats
LNTH vs Market · 30-day return after each reportLNTHS&P 500
−7%0%+7%+14%+3.4%+2.5%Q2 25+13.4%+1.9%Q3 25−3.1%−8.3%Q4 25+9.9%+0.8%Q1 26−0.6%−0.3%Q2 26
−7%0%+7%+14%Q2 25Q3 25Q4 25Q1 26Q2 26
LNTH EPS Trend · estimate vs actualEstimateActual
$0.00$0.50$1.00$1.50$1.68$1.57Q2 25$1.27$1.27Q3 25$1.17$1.67Q4 25$1.23$1.46Q1 26$1.30$1.55Q2 26$1.26$1.68Q3 26
$0.00$0.50$1.00$1.50Q2 25Q4 25Q2 26
LNTH Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$387.9M$378.0MQ2 25$364.5M$384.0MQ3 25$367.0M$406.8MQ4 25$354.4M$377.3MQ1 26$363.2M$388.2MQ2 26$356.7M$389.9MQ3 26
$0$200.0M$400.0MQ2 25Q4 25Q2 26

How Often Does Lantheus Beat Earnings Estimates?

Lantheus beat EPS estimates in 5 of its last 6 reported quarters, and has beaten 5 quarters in a row.

LNTH quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Adjusted EPS excludes a $31.0 million impairment of intangible assets, $46.9 million of acquisition, integration and divestiture-related items, a $12.2 million net loss on investment in equity securities, $21.9 million of stock and incentive plan compensation and $16.7 million of amortization of acquired intangibles; GAAP diluted EPS was $0.33. $1.68 est. $1.26 +33.19% $389.9M est. $356.7M +9.31%
Q2 2026 $1.55 est. $1.30 +18.90% $388.2M est. $363.2M +6.87%
Q1 2026 $1.46 est. $1.23 +18.78% $377.3M est. $354.4M +6.46%
Q4 2025 $1.67 est. $1.17 +42.92% $406.8M est. $367.0M +10.83%
Q3 2025 $1.27 est. $1.27 +0.24% $384.0M est. $364.5M +5.37%
Q2 2025 $1.57 est. $1.68 −6.29% $378.0M est. $387.9M −2.55%

Figures from SEC filings and company reports. Not investment advice.